GenesisCare Reports Increase in Americans Presenting with Advanced Metastatic Cancer in 2020

On October 15, 2020 GenesisCare reported that People delaying their annual cancer screenings and ignoring signs and symptoms of cancer may end up being diagnosed with later-stage metastatic disease reports leading oncology provider (Press release, GenesisCare, OCT 15, 2020, View Source [SID1234568543]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The latest reporting from GenesisCare centers saw an increase in patients presenting with advanced (metastatic) disease, increasing the risk of mortality, and a noticeable decline in reported new patient cases since the COVID-19 pandemic started.

Throughout the 290 GenesisCare cancer treatment locations across the U.S., physicians have recorded a double-digit percentage of declines in new patient cases for curative breast, lung, and prostate cancers.

This decline followed the restrictions on elective medical procedures beginning in March of 2020 as well as reduced visits to primary care and outpatient services.

Key findings include:

– Breast cancer: the percentage of women presenting with stage three or four cancer increased to 18.1% from 12.1% the previous year.
– Lung cancer: the percentage of patients presenting with stage three or four lung cancer also increased to 38% from 32.6% the previous year.

"Across the United States and internationally, we have documented a significant reduction in new cancer diagnoses and an increase in metastatic patients within our large network of cancer treatment centers," Dr. Constantine Mantz, Chief Policy Officer and Radiation Oncologist at GenesisCare’s US offices said.

"We believe this is due to factors including the closure of cancer screening programs, and the general public delaying annual cancer screening appointments due to fears of contracting the virus."

A recent research letter published in JAMA Oncology, researchers found little risk of a COVID-19 infection for cancer patients visiting healthcare facilities, as long as the facility followed all the necessary safety protocols.

"The new national figures around cancer patients presenting at later stage metastatic disease is unprecedented, and the concern is that this may be occurring because people are not participating in screening and following up on symptoms," Dr.Mantz said.

"Early diagnosis and treatment of cancer are critical to improving patients’ outcomes and reducing the risk of mortality."

"We want to remind people of the importance of continuing their annual health screenings and not ignoring early signs and symptoms of cancer," he said.

Founder and Global Chief Executive Officer of GenesisCare, Dan Collins observed that, as one of the largest providers of integrated oncology care in the United States and the world, the GenesisCare team has seen the direct impact of lockdowns and restrictions on cancer treatments during the pandemic.

"Cancer doesn’t stop, and our teams and centers can’t either," Mr Collins said.

"Patients across the country are looking for reassurance that hospitals and healthcare providers are taking the necessary precautions to protect them from COVID-19."

Mr Collins said learning from the early days of the pandemic in Europe the company had increased telehealth options and enhanced safety precautions at its healthcare facilities to ensure patients can be treated safely.

"Since the start of the pandemic, we have implemented stringent safety and quality measures in Australia, the UK, Spain – and now the US – to keep our patients and staff safe."

"Our committed clinical teams understand how vital it is for patients to receive access to their essential care at the right time."

For more information on GenesisCare, visit genesiscare.com (formally 21st Century Oncology). To view the full list of precautions GenesisCare US centers are taking to ensure patient and staff safety, visit View Source

Heska Corporation to Report Third Quarter 2020 Financial Results and Host Earnings Call on November 5, 2020

On October 15, 2020 Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, reported its third quarter 2020 financial performance in a press release before the market opens on Thursday, November 5, 2020 and to host an earnings call to discuss the results following the release at 9 a.m. MT / 11 a.m. ET (Press release, Heska, OCT 15, 2020, View Source [SID1234568542]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call:
From within the United States, please dial 1-866-548-4713
From outside of the United States, please dial 1-323-794-2093
Reference Conference ID: 9707717

The earnings call will be webcast live from the Company’s investor relations website at: Heska Third Quarter 2020 Earnings Call Webcast.

A telephonic replay will be available beginning at 2:00 p.m. ET Thursday, November 5 and will continue through 11:59 p.m. ET on Thursday, November 19, 2020. The webcast will be archived for 90 days.

ViewRay Announces Conference Call for Third Quarter 2020 Financial Results to be Held After Market on November 5, 2020

On October 15, 2020 ViewRay, Inc. (Nasdaq: VRAY) reported details relating to the release of its third quarter 2020 financial results (Press release, ViewRay, OCT 15, 2020, View Source [SID1234568541]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ViewRay will hold a conference call to discuss results on Thursday, November 5, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 9819479. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at View Source

After the live webcast, a replay will remain available online on the investor relations page of ViewRay’s website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until November 12, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 9819479.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2020 Financial Results

On October 15, 2020 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that the Company will host a webcast conference call to report its third quarter 2020 financial results and provide an update on the company’s business and outlook on Thursday, October 29, 2020 at 4:30 p.m. (ET) after the closing of the market (Press release, PTC Therapeutics, OCT 15, 2020, https://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2020-financial-results-301147176.html [SID1234568540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 7096445. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company’s website for 30 days following the call.

BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update

On October 15, 2020 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, reported financial results for the third quarter ended September 30, 2020, and provided a corporate update (Press release, BrainStorm Cell Therapeutics, OCT 15, 2020, View Source [SID1234568538]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The most important near-term event for BrainStorm will be the upcoming top-line data readout for the NurOwn Phase 3 trial in ALS, expected by the end of November. A successful outcome will set us on the path to filing a Biologic License Application (BLA) for what we believe will be a valuable new treatment for ALS," said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. "In parallel to our preparations for upcoming data read out, we are very busy planning and executing on other pre-BLA activities. On the management front, we appointed William K. White and Dr. Anthony Waclawski, adding valuable commercial and regulatory expertise to our leadership team. This expertise will be crucial as we work towards obtaining regulatory approval for NurOwn and ensuring that, if approved, it will be readily accessible to ALS patients in need of new treatment options for this devastating disease."

NurOwn has an innovative mechanism of action that is broadly applicable across neurodegenerative diseases and BrainStorm continues to invest in clinical trials evaluating the product in conditions beyond ALS to maximize value creation for its various stakeholders. The company remains on track to complete dosing in its Phase 2 clinical trial in progressive multiple sclerosis (PMS) by the end of 2020. In addition, the Company recently unveiled a clinical development program in Alzheimer’s’ disease (AD) and is planning a Phase 2 proof-of-concept clinical trial at several leading AD centers in the Netherlands and France.

Third Quarter 2020 and Recent Corporate Highlights:

Completed dosing of all patients in the ongoing NurOwn Phase 3 clinical trial in ALS and plans remains on track to report top-line data by the end of November 2020.
Announced the publication of a manuscript titled "Effects of MSC-NTF cells on T and B regulatory cell function in ALS" in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. The manuscript describes NurOwn’s immunomodulatory effects on T and B regulatory cell function, suggesting that its mechanism of action is broadly applicable in ALS, PMS and Alzheimer’s disease.
Presented a scientific poster titled "Advancing NurOwn for ALS: Phase 3 Clinical Trial Design" at the Annual Northeast ALS (NEALS) Meeting.
A Phase 2 trial evaluating NurOwn as a treatment for progressive multiple sclerosis (PMS) is ongoing at 5 leading U.S. multiple sclerosis centers. The Company remains on track to complete dosing by year end 2020.
Presented progressive MS natural history data at the MSVirtual2020 meeting documenting an association between magnetic resonance imaging (MRI) measures and functional improvement in patients matched to the phase 2 NurOwn clinical trial.
Hosted a Key Opinion Leader (KOL) webinar on the Alzheimer’s disease program and the planned European Phase 2 trial. The webinar featured presentations by two lead investigators in the trial: Philip Scheltens, M.D., Ph.D., Professor of Cognitive Neurology and Director of the Alzheimer Centre at the VU University Medical Center in Amsterdam, Netherlands; and Bruno Dubois, M.D., Ph.D., Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital in Paris, France.
Announced a groundbreaking pre-clinical study of a NurOwn derived exosome-based treatment for COVID-19 acute respiratory distress syndrome (ARDS).
Appointed Anthony Waclawski Ph.D. as Executive Vice President, Global Head of Regulatory Affairs.
Appointed William K. White as Senior Vice President, Head of Market Access and Pricing.
Received a non-dilutive bonus payment of $700,000 from California Institute for Regenerative Medicine (CIRM) for treating more California participants than originally proposed in the Phase 3 ALS trial.
Announced the grant of Japanese Patent No. 6,753,887, titled: "Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors".
Presented at the following Investor Conferences:

40th Annual Canaccord Genuity Growth Conference
Cash and Liquidity as of October 14, 2020

Total available funding as of October 14, 2020, which includes cash, cash equivalents and short-term bank deposits of approximately $33.1 million as well as remaining non-dilutive funding from CIRM, IIA and other grants, amounts to approximately $36 million.

Financial Results for the Three Months Ended September 30, 2020

Cash and cash equivalents, and short-term bank deposits amounted to approximately $28.8 million at September 30, 2020 compared to $16.2 million at June 30, 2020.
Research and development expenses, net for the three months ended September 30, 2020 and 2019 were $1.87 million and $4.01 million, respectively.
Excluding participation from IIA and CIRM under the grants and proceeds received under the hospital exemption regulatory pathway, research and development expenses decreased by $1.68 million from $5.66 million in the third quarter of 2019 to $3.98 million in the third quarter of 2020.
General and administrative expenses for the three months ended September 30, 2020 and 2019 were $2.62 million and $1.54 million, respectively.
Net loss for the three months ended on September 30, 2020 was $4.49 million, as compared to a net loss of $5.63 million for the three months ended September 30, 2019.
Net loss per share for the three months ended September 30, 2020 and 2019 was $0.14 and $0.25, respectively.
Conference Call & Webcast
Thursday, October 15, 2020 at 8 a.m. Eastern Time

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and completed enrollment in August 2020.